Orforglipron and St. John's Wort: Can You Take Them Together?

High: Consult Your DoctorConflict
Learn about each ingredient:OrforglipronSt. John's Wort

Quick answer

Orforglipron (Foundayo) is broken down mainly by the liver enzyme CYP3A4. Its label says to avoid strong CYP3A4 inducers because they lower orforglipron levels and may make it work less well; in a study, the strong inducer carbamazepine cut orforglipron exposure by 82%. The FDA classes St. John's wort as a strong CYP3A inducer, although its effect varies by product. No study has tested St. John's wort with orforglipron, so the size of the drop is predicted from the class, not measured.

Avoid St. John's wort while taking orforglipron unless your prescriber agrees, because it may make the medicine work less well. If you already take both, talk to your prescriber or pharmacist before changing anything, especially if you use St. John's wort for low mood.

Taking more than these two?Check your whole list for interactions. Free, no account.

What happens?

Orforglipron is broken down mainly by the liver enzyme CYP3A4. St. John's wort makes the body produce more of that enzyme, so orforglipron may be cleared faster.

1

Cleared by CYP3A4

The Foundayo label says orforglipron is metabolized primarily by the liver enzyme CYP3A4.

2

The herb speeds up the enzyme

The FDA classes St. John's wort as a strong CYP3A inducer: over days of use, the body makes more of the enzyme.

3

Less medicine

With the strong inducer carbamazepine, orforglipron exposure fell by 82%, which the label says may reduce its effectiveness.

With the strong CYP3A4 inducer carbamazepine, orforglipron exposure fell by <strong>82%</strong>; the FDA classes St. John's wort as a <strong>strong CYP3A inducer</strong>.

Why is this important?

The Foundayo label says to avoid strong CYP3A4 inducers. The herb is in that group even though the label does not name it.

Less effect

Lower orforglipron levels may mean less weight loss for the same dose.

Easy to miss

The label rule covers strong inducers as a group and does not name the herb, and people often do not mention herbal products.

Rebound when stopping

Enzyme activity returns to normal about a week after stopping the herb, so orforglipron levels and side effects could rise again.

Because the enzyme effect fades over about a week after stopping, changes to either one are best planned with your prescriber.

What should you do?

The practical fix is simple: separate the doses.

Avoid St. John's wort while taking orforglipron unless your prescriber agrees

Best practical schedule

Before starting orforglipron
Tell your prescriber about every herbal product, including St. John's wort teas and blends.
While taking orforglipron
Avoid St. John's wort and check mood, sleep and menopause blends for it.
If you already take both
Talk to your prescriber or pharmacist before changing either one; do not change orforglipron on your own.

Important reminders

  • •The FDA classes St. John's wort as a strong CYP3A inducer.
  • •Effects vary by product: high-hyperforin extracts induce the enzyme the most.
  • •The induction fades about a week after stopping the herb.
  • •If you use the herb for low mood, ask your prescriber about options that suit orforglipron.

This warning is predicted from the label rule for strong inducers and the FDA classification of the herb; no study has tested the pair directly.

Which specific products are affected?

Many common St. John's Wort products can affect this interaction.

Orforglipron products

Foundayo (orforglipron) tablets

Where St. John's wort is found

St. John's wort (Hypericum perforatum) capsules and tabletsSt. John's wort tinctures and teasMulti-herb mood and stress formulasSleep blendsMenopause support blends

Other sources

  • •Products with more hyperforin induce CYP3A4 more; low-hyperforin products induce it less, but none has been tested with orforglipron.

Read the labels of multi-ingredient herbal blends, where St. John's wort may be listed as Hypericum perforatum.

The bottom line

Orforglipron is cleared mainly by CYP3A4, and its label says to avoid strong CYP3A4 inducers because they lower orforglipron levels and may make it work less well. The FDA classes St. John's wort as a strong CYP3A inducer. Avoid the herb while taking orforglipron unless your prescriber agrees.

No study has tested this pair directly. If you already take both, talk to your prescriber or pharmacist before changing either one.

What happens when you take orforglipron with st. john's wort?

Orforglipron (Foundayo) is a once-daily GLP-1 receptor agonist tablet approved to help adults with obesity, or overweight with a weight-related condition, lose weight and keep it off, together with diet and exercise. St. John's wort (Hypericum perforatum) is an herbal product sold for low mood. The herb speeds up the enzyme that breaks down orforglipron, so less of the medicine may stay in the body.

  1. Orforglipron is cleared by CYP3A4. The Foundayo label says it is metabolized primarily by the liver enzyme CYP3A4.
  2. St. John's wort induces CYP3A4. The FDA lists it as a strong CYP3A inducer: over days of use, the body makes more of the enzyme.
  3. Orforglipron levels fall. With carbamazepine, another strong inducer, orforglipron exposure dropped by 82%.
  4. The medicine may work less well. The label says lower exposure may reduce the effectiveness of Foundayo.

Why is this important?

The Foundayo label tells prescribers to avoid strong CYP3A4 inducers with Foundayo. It does not name St. John's wort, but the FDA places the herb in that same strong-inducer group. People may not think of an herbal product as a medicine and may not mention it, so the prescriber may not know.

The concern is mainly loss of effect: less weight loss for the same dose. There is a second, quieter issue. Induction fades over about a week after the herb is stopped, so orforglipron levels would climb back up, which could bring more of its usual side effects such as nausea, vomiting and diarrhea. That is why a change in either one is best planned with your prescriber.

What should you do?

Before starting orforglipron: Tell your prescriber about every herbal product you take, including St. John's wort in teas or blends.

While taking orforglipron: Avoid St. John's wort unless your prescriber agrees. Check the labels of mood, sleep, stress and menopause blends, where the herb is often included.

If you already take both: Do not stop or change orforglipron on your own. Talk to your prescriber or pharmacist before stopping the herb too, especially if you use it for low mood, so your mood and your orforglipron dose can be looked after together.

Which specific products are affected?

On the medication side, this applies to Foundayo (orforglipron) tablets.

On the herb side, it applies to any Hypericum perforatum product: capsules, tablets, tinctures, teas, and multi-herb blends for mood, sleep, stress or menopause. Products with more hyperforin, a constituent of the herb, induce the enzyme more; low-hyperforin products induce it less, but none has been tested with orforglipron.

The science behind it

The Foundayo prescribing information (DailyMed, sections 2.2, 7.1 and 12.3) says to avoid concomitant use with strong CYP3A4 inducers because induction decreases Foundayo exposure, "which may reduce the effectiveness of FOUNDAYO." In its drug interaction table, carbamazepine (a strong inducer) lowered orforglipron AUC by 82% and peak level by 55%; a computer model predicted a 61% drop with efavirenz (a moderate inducer). With moderate inducers, the label says to monitor effectiveness. Orforglipron has an elimination half-life of about 29 to 49 hours.

The FDA table of drugs that interact with CYP enzymes (fda.gov) lists St. John's wort as a strong CYP3A inducer, with a footnote that its effect varies widely and is preparation dependent.

Human studies show how strong the herb's effect can be. Dresser GK, et al. (Clin Pharmacol Ther. 2003; PMID 12545142) gave 21 healthy young adults St. John's wort for 12 days; the oral clearance of midazolam, a CYP3A test drug, rose about 2.7-fold. Mueller SC, et al. (Eur J Clin Pharmacol. 2006; PMID 16341856) tested six St. John's wort products in 42 healthy men for 14 days: a high-hyperforin extract cut midazolam exposure by 79.4%, and a product almost free of hyperforin cut it by 21.1%. Imai H, et al. (Br J Clin Pharmacol. 2008; PMID 18294328) found that in 12 healthy men, CYP3A activity returned to baseline about 7 days after stopping the herb.

What was not shown: no study has given St. John's wort with orforglipron, and no study has measured weight loss in people taking both. The warning is based on the label rule for strong inducers and the FDA's classification of the herb.

Frequently Asked Questions

Can I take St. John's wort with Foundayo?

It is best avoided unless your prescriber agrees. The Foundayo label says to avoid strong CYP3A4 inducers, and the FDA classes St. John's wort as one.

Will St. John's wort stop Foundayo from working?

It may make it work less well. A strong inducer cut orforglipron exposure by 82% in a study; the effect of St. John's wort itself has not been measured and depends on the product.

Is St. John's wort tea a problem too?

It can be. Teas, tinctures and blends contain the same herb, though the amount of hyperforin varies. Check labels and ask your pharmacist.

What if I stop St. John's wort?

The enzyme effect fades over about a week, so orforglipron levels would rise back toward normal, which could bring more nausea or other side effects. Plan the change with your prescriber or pharmacist.

Does this apply to other weight-loss medicines?

This page is about orforglipron, whose label sets the rule on strong CYP3A4 inducers. Other medicines have their own labels, so ask your pharmacist about St. John's wort with any of them.

Key takeaways

  • Orforglipron is cleared mainly by CYP3A4, and its label says to avoid strong CYP3A4 inducers.
  • The FDA classes St. John's wort as a strong CYP3A inducer, with effects that vary by product.
  • A strong inducer cut orforglipron exposure by 82%; the herb itself has not been tested with it.
  • The main risk is that orforglipron works less well.
  • Tell your prescriber about St. John's wort, and plan any change to either one with your prescriber or pharmacist.

References

Primary evidence for this article. Always consult your healthcare provider for personal medical advice.

Related Interactions

Other interactions you should know about

Venlafaxine + St. John's Wort

critical

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). St. John's wort independently inhibits serotonin (and to a lesser extent norepinephrine and dopamine) reuptake. Combining them can drive synaptic serotonin higher and trigger serotonin syndrome, and the Effexor XR label lists St. John's Wort as a serotonin syndrome risk. St. John's wort also induces CYP3A4, one of the enzymes that clears venlafaxine, but whether it lowers venlafaxine levels has not been measured.

Digoxin + St. John's Wort

high

St. John's wort revs up a gut transporter that digoxin depends on for absorption, so combining them quietly drains digoxin from the bloodstream. Because digoxin has so little room to spare, that drop can leave the drug too weak to control your heart.

Seville Orange + Red Yeast Rice

high

Seville orange contains furanocoumarins that inhibit intestinal CYP3A4, the enzyme that clears the monacolin K in red yeast rice. Because monacolin K is chemically identical to the statin lovastatin and depends on CYP3A4 for its first-pass breakdown, blocking that enzyme raises systemic exposure to the active statin, increasing the risk of muscle-related side effects such as myopathy and, rarely, rhabdomyolysis.

St. John's Wort + Red Yeast Rice

moderate

St. John's wort is a strong inducer of the CYP3A4 enzyme system that clears the statin-like compound (monacolin K, chemically identical to lovastatin) in red yeast rice. Taking them together speeds up how the body breaks down that compound, lowering its levels and weakening red yeast rice's cholesterol-lowering effect. The concern here is loss of benefit rather than toxicity, and the direction is the opposite of CYP3A4-inhibitor interactions, so it does not raise muscle-injury risk.

Pomelo + Red Yeast Rice

high

Pomelo, like grapefruit, contains furanocoumarins that inhibit the intestinal CYP3A4 enzyme. Red yeast rice's active constituent, monacolin K, is chemically identical to the statin lovastatin, which depends on CYP3A4 for its breakdown. When pomelo blocks that enzyme, more of the monacolin K reaches the bloodstream, amplifying the dose-dependent statin-type risks of muscle injury and, rarely, liver enzyme elevation. Because furanocoumarin inhibition can persist for days, the effect is not reliably avoided by taking the two at different times of day.

Grapefruit + Sirolimus

high

Sirolimus is a CYP3A4 and P-glycoprotein substrate with a narrow therapeutic window and wide patient-to-patient variability. The FDA sirolimus label says grapefruit juice inhibits the CYP3A4-mediated metabolism of sirolimus and must not be taken with, or used to dilute, the drug. In phase 1 studies in adults with advanced cancer, grapefruit juice raised sirolimus exposure about 350%. Unplanned rises in blood levels can cause sirolimus toxicity.

Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making changes to your supplement or medication routine. Pilora does not diagnose, treat, cure, or prevent any disease.

Check all your supplement interactions instantly

Try Pilora Free